TKPYY - Takeda Pharmaceutical Company Limited
Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Income Statement
Annual
| Revenue | 3/31/2017 | 3/31/2016 | 3/31/2015 | 3/31/2014 |
| Total Revenue | 1,732,051,000 | 1,807,378,000 | 1,777,824,000 | 1,691,685,000 |
| Cost of Revenue | 557,676,000 | 535,115,000 | 520,213,000 | 490,263,000 |
| Gross Profit | 1,174,375,000 | 1,272,263,000 | 1,257,611,000 | 1,201,422,000 |
| Operating Expenses | ||||
| Research Development | 311,625,000 | 335,704,000 | 367,741,000 | 341,560,000 |
| Selling General and Administrative | 615,867,000 | 650,336,000 | 612,489,000 | 556,210,000 |
| Non Recurring | - | - | - | - |
| Others | 4,332,000 | 155,000 | -2,087,000 | 8,012,000 |
| Total Operating Expenses | 1,601,608,000 | 1,643,095,000 | 1,621,577,000 | 1,539,247,000 |
| Operating Income or Loss | 130,443,000 | 164,283,000 | 156,247,000 | 152,438,000 |
| Income from Continuing Operations | ||||
| Total Other Income/Expenses Net | 12,903,000 | -43,745,000 | -301,684,000 | 6,412,000 |
| Earnings Before Interest and Taxes | 130,443,000 | 164,283,000 | 156,247,000 | 152,438,000 |
| Interest Expense | -7,560,000 | -5,271,000 | -5,796,000 | -4,888,000 |
| Income Before Tax | 143,346,000 | 120,538,000 | -145,437,000 | 158,850,000 |
| Income Tax Expense | 27,833,000 | 37,059,000 | -2,403,000 | 49,292,000 |
| Minority Interest | 54,704,000 | 62,511,000 | 69,129,000 | 69,896,000 |
| Net Income From Continuing Ops | 115,513,000 | 83,479,000 | -143,034,000 | 109,558,000 |
| Non-recurring Events | ||||
| Discontinued Operations | - | - | - | - |
| Extraordinary Items | - | - | - | - |
| Effect Of Accounting Changes | - | - | - | - |
| Other Items | - | - | - | - |
| Net Income | ||||
| Net Income | 114,940,000 | 80,166,000 | -145,775,000 | 106,658,000 |
| Preferred Stock And Other Adjustments | - | - | - | - |
| Net Income Applicable To Common Shares | 114,940,000 | 80,166,000 | -145,775,000 | 106,658,000 |
